Cadrenal Therapeutics, Inc. (CVKD) has released an update.
Cadrenal Therapeutics, Inc. has appointed Jeffrey Cole as their new Chief Operating Officer, solidifying the decision with a comprehensive employment agreement. Cole, an industry veteran with over 25 years of experience, has a history of significant roles in pharmaceuticals and consulting. His compensation includes a $405,000 base salary, potential for a 40% bonus, and robust severance and equity vesting terms. His appointment, which brings a wealth of knowledge and expertise to the company, was publicly announced on February 8, 2024.
For further insights into CVKD stock, check out TipRanks’ Stock Analysis page.
